Verification evidence is still being completed.
PDF / print export
Oncoinvent ASA
Oslo, Norway
- Verified lead
- Oystein Soug
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Alpha-Emitter Radiopharmaceuticals, Radium-224 Microspheres, and Ovarian Peritoneal Metastases
- Review cycle
- 24 April 2026
- Full address
- Gullhaugveien 7, 0484 Oslo, Norway (Nydalen)
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Oncoinvent management page listing Oystein Soug as Chief Executive Officer.
- Editorial note
- Oslo-listed clinical-stage radiopharmaceutical developer with GMP manufacturing authorization for clinical material, FDA Fast Track for Radspherin, and a 2025 BerGenBio merger that consolidated capital and listing.
Alpha-Emitter Radiopharmaceuticals, Radium-224 Microspheres, and Ovarian Peritoneal Metastases
GMP manufacturing authorization from NoMA, FDA Fast Track for Radspherin, Documented 2025 BerGenBio merger
Oslo-listed clinical-stage radiopharmaceutical developer with GMP manufacturing authorization for clinical material, FDA Fast Track for Radspherin, and a 2025 BerGenBio merger that consolidated capital and listing.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Oslo, Norway
Oncoinvent ASA
Alpha-Emitter Radiopharmaceuticals, Radium-224 Microspheres, and Ovarian Peritoneal Metastases · GMP clinical-trial-material production
Oslo-listed clinical-stage radiopharmaceutical developer with GMP manufacturing authorization for clinical material, FDA Fast Track for Radspherin, and a 2025 BerGenBio merger that consolidated capital and listing.
- Lead
- Oystein Soug (verified ↗)
- Address
- Gullhaugveien 7, 0484 Oslo, Norway (Nydalen) (source ↗)
- Compliance
- GMP manufacturing authorization from NoMA · FDA Fast Track for Radspherin
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- GMP clinical-trial-material production
- Capabilities
- Alpha-Emitter Radionuclide Formulation · Radium-224 Microsphere Manufacturing · Phase 2 Ovarian Cancer Clinical Operations
- Founded
- 2015
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Oystein Soug
Chief Executive Officer
Full addressGullhaugveien 7, 0484 Oslo, Norway (Nydalen)
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Oncoinvent contact page listing Gullhaugveien 7, 0484 Oslo as the Nydalen office.
Open sourceGMP clinical-trial-material production
Oslo, Norway. Alpha-Emitter Radiopharmaceuticals, Radium-224 Microspheres, and Ovarian Peritoneal Metastases. Review completed on 24 Apr 2026.
Norwegian Medicines Agency, EMA, and FDA for clinical-stage radiopharmaceutical development
GMP manufacturing authorization from NoMA, FDA Fast Track for Radspherin, Documented 2025 BerGenBio merger
Alpha-Emitter Radiopharmaceuticals, Radium-224 Microspheres, and Ovarian Peritoneal Metastases
Oslo-listed clinical-stage radiopharmaceutical developer with GMP manufacturing authorization for clinical material, FDA Fast Track for Radspherin, and a 2025 BerGenBio merger that consolidated capital and listing.
Editorial note
Oncoinvent anchors Norwegian clinical-stage radiopharmaceutical development with documented Norwegian Medicines Agency manufacturing authorization for clinical trial material, FDA Fast Track for Radspherin in ovarian peritoneal metastases, and a 2025 merger with BerGenBio that consolidated capital and Oslo listing.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Alpha-Emitter Radionuclide Formulation
Radium-224 Microsphere Manufacturing
Phase 2 Ovarian Cancer Clinical Operations
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Radium-224 microsphere production
GMP manufacturing suite for clinical material
Phase 2 ovarian-cancer trial operations
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Oncoinvent ASA located?
- Oncoinvent ASA operates from Gullhaugveien 7, 0484 Oslo, Norway (Nydalen), Oslo, Norway.
- Who runs Oncoinvent ASA?
- Oncoinvent ASA is led by Oystein Soug, Chief Executive Officer. Verified 24 Apr 2026.
- What certifications does Oncoinvent ASA hold?
- Oncoinvent ASA is documented under GMP manufacturing authorization from NoMA, FDA Fast Track for Radspherin.
- What does Oncoinvent ASA do?
- Oslo-listed clinical-stage radiopharmaceutical developer with GMP manufacturing authorization for clinical material, FDA Fast Track for Radspherin, and a 2025 BerGenBio merger that consolidated capital and listing. Core capabilities: Alpha-Emitter Radionuclide Formulation, Radium-224 Microsphere Manufacturing, Phase 2 Ovarian Cancer Clinical Operations.
Editorial context
Related technical briefs
Briefs that name Oslo as a covered market or city.